First approval in Latin America for AirFluSal

Vectura Group plc

First approval in Latin America for innovative respiratory inhaler AirFluSal® Forspiro®

· Mexico's Health Authority (COFEPRIS) grants marketing authorisation for AirFluSal® Forspiro®

· Approval for 50-100 mg, 50-250 mg and 50-500 mg dosage forms

· Product to be branded IrFlosol™ Forspiro® in Mexico

· Airflusal® Forspiro® already launched in four European countries as well as in South Korea

Chippenham, UK - 21 August 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner Sandoz, has been granted marketing authorisation by the Mexican Health Authority (COFEPRIS) for AirFlusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

The approval in Mexico is the first in Latin America and follows the marketing authorisations in a total of eight European countries as well as in South Korea. Four European countries have already launched AirFluSal® Forspiro® in addition to the launch in May 2014 in South Korea.

Mexico has approved Airflusal® Forspiro® in the 50-100 µg, 50-250 µg and 50-500 µg dosage forms and the product will be branded IrFlosol™ Forspiro®.

AirFluSal® Forspiro® offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product's safety, efficacy and equivalence have been proven in multiple clinical trials. Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.

-Ends-

Enquiries

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.1

Vectura has eight products marketed by partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has disclosed development collaborations and licence agreements with several pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company Limited.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.

References

1 Pharmaview Commercial Landscape Series Respiratory Decision Resources 2013

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.